- Home
- PSNL vs PMVP Comparison
PSNL vs PMVP Comparison
Compare PSNL & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNL
- PMVP
- Stock Information
- Founded
- PSNL 2011
- PMVP 2013
- Country
- PSNL United States
- PMVP United States
- Employees
- PSNL N/A
- PMVP N/A
- Industry
- PSNL Medical Specialities
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- PSNL Health Care
- PMVP Health Care
- Exchange
- PSNL Nasdaq
- PMVP Nasdaq
- Market Cap
- PSNL 321.1M
- PMVP 85.5M
- IPO Year
- PSNL 2019
- PMVP 2020
- Fundamental
- Price
- PSNL $5.19
- PMVP $1.65
- Analyst Decision
- PSNL Strong Buy
- PMVP Strong Buy
- Analyst Count
- PSNL 4
- PMVP 4
- Target Price
- PSNL $6.81
- PMVP $5.75
- AVG Volume (30 Days)
- PSNL 439.4K
- PMVP 185.0K
- Earning Date
- PSNL 11-06-2024
- PMVP 11-07-2024
- Dividend Yield
- PSNL N/A
- PMVP N/A
- EPS Growth
- PSNL N/A
- PMVP N/A
- EPS
- PSNL N/A
- PMVP N/A
- Revenue
- PSNL $80,027,000.00
- PMVP N/A
- Revenue This Year
- PSNL $10.85
- PMVP N/A
- Revenue Next Year
- PSNL $8.77
- PMVP N/A
- P/E Ratio
- PSNL N/A
- PMVP N/A
- Revenue Growth
- PSNL 19.20
- PMVP N/A
- 52 Week Low
- PSNL $0.89
- PMVP $1.33
- 52 Week High
- PSNL $7.20
- PMVP $3.47
- Technical
- Relative Strength Index (RSI)
- PSNL 56.29
- PMVP 60.86
- Support Level
- PSNL $4.54
- PMVP $1.63
- Resistance Level
- PSNL $5.35
- PMVP $1.69
- Average True Range (ATR)
- PSNL 0.30
- PMVP 0.07
- MACD
- PSNL 0.05
- PMVP 0.01
- Stochastic Oscillator
- PSNL 84.71
- PMVP 52.65
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.